Feb 9, 2026 08:00AM
Feb 5, 2026 06:30PM
Feb 5, 2026 06:30PM
Jan 14, 2026 08:25PM
Dec 17, 2025 08:00AM
Dec 9, 2025 06:06AM
Dec 9, 2025 06:06AM Ascentage Pharma reports phase III data for leukemia drug candidate
Dec 9, 2025 06:06AM
Dec 8, 2025 07:45PM
Dec 8, 2025 07:45PM
Dec 8, 2025 07:45PM
Dec 7, 2025 08:10PM
Dec 6, 2025 10:15AM
Dec 4, 2025 07:00PM Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
Dec 1, 2025 08:00AM
Nov 24, 2025 07:00PM
Nov 19, 2025 08:00AM
Nov 3, 2025 08:10PM
Nov 3, 2025 08:10PM
Oct 29, 2025 08:00PM
Oct 7, 2025 08:00AM Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
Aug 25, 2025 08:00AM
Aug 20, 2025 07:57PM
Aug 17, 2025 07:30PM
Aug 1, 2025 08:00AM
Jul 23, 2025 08:00AM
Jul 17, 2025 04:30AM
Jul 14, 2025 10:36AM Ascentage Pharma prices $192.3 million share placement at HKD68.60
Jul 14, 2025 10:35AM
Jul 14, 2025 05:57AM
Jul 14, 2025 05:23AM
Jul 10, 2025 09:31AM
Jul 10, 2025 09:30AM
Jul 7, 2025 07:30PM
Jun 15, 2025 07:30PM EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
Jun 9, 2025 07:30PM
Jun 2, 2025 07:30PM
Jun 2, 2025 07:30PM
May 22, 2025 08:15PM
Apr 23, 2025 07:00PM
Apr 21, 2025 07:01AM
Apr 21, 2025 07:00AM Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
Mar 25, 2025 07:00PM
Feb 7, 2025 08:25AM
Feb 7, 2025 08:24AM
Jan 28, 2025 04:01PM
Jan 24, 2025 11:03AM

118,853 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All